Of note, in the last years, the growing clinical use of innovative immunotherapies targeting CD19 (i.e., blinatumomab and CAR-T cells) and CD22 (inotuzumab ozogamicin) have suggested to extend MFC-MRD analysis to CD22 and CD24, which are expressed in early BCPs (even before CD19), and can be essential for tracking B-ALL clones with persistent downregulation of CD19 (frequently occurring after targeted treatments), as well as for the identification of CD22+ cases eligible for inotuzumab ozogamicin [51]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.